Pall Recommendations for Virus Validation Studies

Pall Recommendations for Virus Validation Studies

Many biopharmaceutical therapies, such as mAbs and blood plasma factors, are produced using biological materials. This carries the risk that microorganisms such as viral contaminants may be unintentionally introduced into the manufacturing process and contaminate the product.  Thus of paramount importance is the removal of such adventitious agents using effective viral filtration methods.

 

In this webinar, the fundamental principles of virus filtration as well as its practical execution will be discussed.  In addition, participants will gain an in-depth understanding of filterability, validation and the local regulatory framework surrounding virus filtration processes.  By the conclusion of the session, all attendees should be able to conduct a virus filterability trial and will be well equipped to have appropriate discussions with validation labs.

 

Participants will learn:

 

  • Regulatory framework
  • Principles of virus filtration
  • How to maximize virus safety at minimized cost
  • How to validate continuous viral clearance process

Speakers

 

 

Charlotte Masy

Morven McAlister, Ph.D.

Global Sr. Director, Regulatory and Validation Consultancy
Pall Biotech

 

Dr Morven McAlister is the Global Senior Director of the Regulatory and Validation Consultancy team at Pall Biotech. She is currently involved in using Quality by Design (QbD) principles for new process applications, product, and method development, as well as supporting microbial risk mitigation practices for end-users. She is also actively involved in various industry task forces (e.g. BPOG, PDA, ASTM) to standardize methods and technical positioning around microbial contamination control.

 

 

Charlotte Masy

Nigel B. Jackson

Principal Engineer R&D
Pall Biotech

 

Since his PhD in Biochemical Engineering, Nigel Jackson has over 10 years of experience in Biotech Process R&D within Pall Biotech. Nigel has multiple publications and conference presentations demonstrating a deep understanding of virus filtration and general bioprocessing. He has directed this knowledge into helping Pall develop robust and effective new virus filters and many other Pall Biotech products and applications. He has also recently taken on the role of Visiting Lecturer at University College London.

 

 

Charlotte Masy

Aernout Martens

Global Product Manager Virus Filtration
Pall Biotech

 

Aernout Martens holds a Master degree in Bioprocess Engineering and a PhD in Physical Chemistry. After his post-doc research on extracellular matric ligand interactions, he started working at Pall as a bio-purification specialist, after which he specialized in virus filtration and became global product manager for the Pall virus filter portfolio.

 

 

Charlotte Masy

Sudhakar Nagaraj

Principal Scientist, SLS – Global Regulatory and Validation Consulting Group
Pall Biotech

 

Sudhakar Nagaraj has been in Pharmaceutical industry for over 18 years and has held positions of increasing responsibility in Pharmaceutical QC/QA, R&D, Validations and Regulatory affairs. He joined Pall during 2006 in Scientific Laboratory Services (SLS) organization and has been involved in updating Pall’s technical support portfolios with rapidly evolving end-user and regulatory requirements, to streamline customer selection, adoption and successful regulatory approval of Pall technologies.

 

 

Download our eBook on Virus Safety

Practical solutions for risk control

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
October 2020

From October 6th to November 19th

 

There is no single vaccine manufacturing approach. There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale.

 

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

 

Diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist.

 

There are flexible technologies that can meet each of the challenges during PD and at GMP scale.

 

Join this webinar series and learn more about securing process quality with flexible manufacturing solutions.

 

Webinars available

 

  • Vaccines development, regulations and manufacturing Parts 1 & 2

 

  • Developing scalable upstream workflows for recombinant and viral vaccine processes

 

  • Downstream process development for vaccine manufacturing

 

  • Implementing single-use technologies in formulation and filling of vaccines
Register